MEIP - MEI Pharma Inc
IEX Last Trade
3.1
-0.160 -5.161%
Share volume: 27,061
Last Updated: Fri 30 Aug 2024 09:59:45 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$3.26
-0.16
-4.91%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 2022-09-08 | 2022-11-14 | 2023-02-09 | 2023-05-11 | 2023-09-26 | 2023-11-09 | 2024-02-13 | 2024-05-09 | |
| Total revenue | 11.414 M | 8.730 M | 32.735 M | 5.894 M | 1.457 M | 65.297 M | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 11.414 M | 8.730 M | 32.735 M | 5.894 M | 1.457 M | 65.297 M | 0.000 | 0.000 | |
| -23.51% | 274.97% | -81.99% | -75.28% | 4,381.61% | -100.00% | nan% | |||
| Operating expenses | 27.610 M | 26.949 M | 23.809 M | 22.285 M | 12.537 M | 10.016 M | 11.930 M | 9.829 M | |
| Selling general and admin | 5.771 M | 7.486 M | 8.496 M | 7.181 M | 9.967 M | 6.531 M | 8.018 M | 4.609 M | |
| Research and development | 21.839 M | 19.463 M | 15.313 M | 15.104 M | 2.570 M | 3.485 M | 3.912 M | 5.220 M | |
| Total expenses | 27.610 M | 26.949 M | 23.809 M | 22.285 M | 12.537 M | 10.016 M | 11.930 M | 9.829 M | |
| -2.39% | -11.65% | -6.40% | -43.74% | -20.11% | 19.11% | -17.61% | |||
| Operating income | -16.196 M | -18.219 M | 8.926 M | -16.391 M | -11.080 M | 55.281 M | -11.930 M | -9.829 M | |
| Ebit | -16.196 M | -18.219 M | 8.926 M | -16.391 M | -11.080 M | 55.281 M | -11.930 M | -9.829 M | |
| Pretax income | -16.063 M | -16.624 M | 10.253 M | -15.438 M | -10.029 M | 56.374 M | -11.063 M | -9.127 M | |
| 3.49% | -161.68% | -250.57% | -35.04% | -662.11% | -119.62% | -17.50% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -16.063 M | -16.624 M | 10.253 M | -15.438 M | -10.029 M | 56.374 M | -11.063 M | -9.127 M | |
| -3.49% | 161.68% | -250.57% | 35.04% | 662.11% | -119.62% | 17.50% | |||
| Net income | -16.063 M | -16.624 M | 10.253 M | -15.438 M | -10.029 M | 56.374 M | -11.063 M | -9.127 M | |
| -3.49% | 161.68% | -250.57% | 35.04% | 662.11% | -119.62% | 17.50% |